Cited by 1,147Multiple Myeloma Research and TreatmentsBone health and treatmentsProtein Degradation and Inhibitors

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Open access

McCarthy, Philip L., Owzar, Kouros, Hofmeister, Craig C., Hurd, David D., Hassoun, Hani, Richardson, Paul G., Giralt, Sergio, Stadtmauer, Edward A., Weisdorf, Daniel J., Vij, Ravi, Moreb, Jan S., Callander, Natalie Scott, Van Besien, Koen, Gentile, Teresa, Isola, Luis, Maziarz, Richard T., Gabriel, Don A., Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H., Levitan, Denise, McClune, Brian, Schlossman, Robert, Hars, Vera, Postiglione, John, Jiang, Chen, Bennett, Elizabeth, Barry, Susan, Bressler, Linda, Kelly, Michael, Seiler, Michele, Rosenbaum, Cara, Hari, Parameswaran, Pasquini, Marcelo C., Horowitz, Mary M., Shea, Thomas C., Devine, Steven M., Anderson, Kenneth C., Linker, Charles·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1114083PMC PMC3744390

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. METHODS: Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). RESULTS: The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 35 patients who received lenalidomide (15%) and 53 patients who received placebo (23%) died (P=0.03). More grade 3 or 4 hematologic adverse events and grade 3 nonhematologic adverse events occurred in patients who received lenalidomide (P<0.001 for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%). CONCLUSIONS: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00114101.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1114083

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Analysis of Survival Data
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,269
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citation
Multiple Myeloma
Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Self-citation
The Statistical Analysis of Failure Time Data
Klein, J. P., Kalbfleisch, J. D., & Prentice, R. L. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,248
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Multiple myeloma
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Self-citation

Show all 42 references

Research works printed but not linked: 2

10.1001/archinte.135.1.147 · DOI
10.2307/2281868 · DOI · Paper page

Sorted by citations

Items 501–600 of 1,000

Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia
Papanikolaou, X. D., Rosenbaum, E. R., Tyler, L. N., Sawyer, J. R., Heuck, C. J., Barlogie, B., & Cottler‐Fox, M. (2013) · Leukemia · doi:10.1038/leu.2013.214 · Cited by 15
Risk of skin cancer in multiple myeloma patients: a retrospective cohort study
Robinson, A. A., Wang, J., Vardanyan, S., Madden, E., Hebroni, F., Udd, K. A., Spektor, T. M., Nosrati, J. D., Kitto, A., Zahab, M., et al. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12748 · Cited by 15
Stem cell transplantation for multiple myeloma: current and future status
Giralt, S., & Bensinger, W. (2013) · Leukemia Supplements · doi:10.1038/leusup.2013.3 · Cited by 14
Self-citation
Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma
Kuroda, J., Nagoshi, H., Shimura, Y., & Taniwaki, M. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.829641 · Cited by 14
The role of tandem stem cell transplantation for multiple myeloma patients
Martino, M. V., Recchia, A. G., Fedele, R., Neri, S., Vincelli, I. D., Moscato, T., Gentile, M., & Morabito, F. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1136285 · Cited by 14
Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry
Rifkin, R. M., Jagannath, S., Durie, B. G. M., Narang, M., Terebelo, H. R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Wagner, L. I., Parikh, K., et al. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.05.017 · Cited by 14
Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them
Chhabra, S., Szabó, A., Glisch, C., George, G., Narra, R. K., Harrington, A. M., Jerkins, J. H., D’Souza, A., Dhakal, B., Pasquini, M. C., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.02.020 · Cited by 14
Self-citation
Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005–2016
Toppila, I., Kysenius, K., Miettinen, T. A., Lassenius, M. I., Lievonen, J., & Anttila, P. M. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04959-9 · Cited by 14
Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Beaussant, Y., Daguindau, É., Pugin, A., Mohty, M., Avet‐Loiseau, H., Roos‐Weil, D., Michallet, M., Chevalier, P., Raus, N., Cheikh, J. E., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.04.020 · Cited by 14
Maintenance therapy for multiple myeloma in the era of novel agents
Facon, T. T. F. (2015) · Hematology · doi:10.1182/asheducation-2015.1.279 · Cited by 14
Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
Suzuki, K., Sunami, K., Ohashi, K., Iida, S., Mori, T., Handa, H., Matsue, K., Miyoshi, M., Bleickardt, E. W., Matsumoto, M., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.18 · Cited by 14
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against
Richardson, P. G. G., Holstein, S. A., Schlossman, R. L., Anderson, K. C., Attal, M., & McCarthy, P. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409207 · Cited by 14
Self-citation
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response
Mina, R., Petrucci, M. T., Corradini, P., Spada, S., Patriarca, F. F., Cerrato, C., Paoli, L. D., Pescosta, N., Ria, R., Malfitano, A., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.05.019 · Cited by 14
Clinical treatment of newly diagnosed multiple myeloma
Cejalvo, M. J., & de la Rubia, J. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1078236 · Cited by 14
Patient with Refractory Multiple Myeloma Developing Eosinophilia after Lenalidomide Treatment and Lung Cancer 9 Months Later: Case Report and Review of the Literature
Sekiguchi, Y., Shimada, A., Imai, H., Wakabayashi, M., Sugimoto, K., Nakamura, N., Sawada, T., Komatsu, N., & Noguchi, M. (2014) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-014-0355-7 · Cited by 14
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*
Ogunniyi, A., Rodríguez, M., Devlin, S. M., Adel, N. G., Landau, H. J., Chung, D. J., Lendvai, N. K., Lesokhin, A. M., Koehne, G., Mailankody, S., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1239261 · Cited by 14
Self-citation
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)
Brioli, A., Manz, K. M., Pfirrmann, M., Hänel, M., Schwarzer, A. C., Prange‐Krex, G., Fabisch, C., Knop, S. T., Illmer, T., Krammer‐Steiner, B., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03101-z · Cited by 14
Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
McCarthy, P. L. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0006 · Cited by 13
Self-citation
Lenalidomide and second malignancies in myeloma patients
Pratt, G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70001-4 · Cited by 13
Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations
Matarraz, S., Paiva, B., Díez‐Campelo, M., Bárrena, S., Jara‐Acevedo, M., Gutiérrez, M. L., Sayagués, J. M., Sánchez, M.-L., Bárcena, P., Garrastazul‐Sánchez, M. P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.103 · Cited by 13
Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle
Malek, E., El‐Jurdi, N., Kröger, N. M., & Lima, M. J. G. D. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00287 · Cited by 13
Maintenance and continuous therapy for multiple myeloma
Richardson, P. G. G., Laubach, J. P., Gandolfi, S., Facon, T. T. F., Weisel, K. C., & O’Gorman, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1490181 · Cited by 13
Self-citation
Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
Byun, J. M., Lee, J., Shin, S.-J., Kang, M., Yoon, S., & Koh, Y. (2018) · Blood Research · doi:10.5045/br.2018.53.2.105 · Cited by 13
Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation
For the Fukuoka Blood and Marrow Transplantation Group, Yamasaki, S., Yoshimoto, G., Kohno, K., Henzan, H., Aoki, T., Tanimoto, K., Sugio, Y., Muta, T., Kamimura, T., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2538-8 · Cited by 13
One-pot method to construct isoindolinones and its application to the synthesis of DWP205109 and intermediate of Lenalidomide
Wang, H., Xie, Z., Lu, B., Zhong, K., Lu, J., & Liu, J. (2021) · Tetrahedron Letters · doi:10.1016/j.tetlet.2021.153152 · Cited by 13
Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant
Karam, D., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Dingli, D., Buadi, F. K., Kapoor, P., Kourelis, T., Warsame, R. M., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01631-8 · Cited by 13
Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
Al‐Mansour, Z., & Ramanathan, M. (2014) · Advances in Hematology · doi:10.1155/2014/652395 · Cited by 13
Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work
Bashir, Q., & Qazilbash, M. H. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0374-1 · Cited by 13
Self-citation
Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma
Koomen, D. C., Meads, M. B., Magaletti, D. M., Guingab-Cagmat, J. D., Oliveira, P. S., Fang, B., Liu, M., Welsh, E. A., Meke, L. E., Jiang, Z., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00022 · Cited by 13
Have drug combinations supplanted stem cell transplantation in myeloma?
Palumbo, A. P., & Cavallo, F. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.335.3792205 · Cited by 13
Direct One-Pot Cobalt(ii) Phthalocyanine Catalyzed Synthesis of N-Substituted Isoindolinones
Kumar, V., Sharma, U. K., Singh, B., & Kumar, N. (2012) · Australian Journal of Chemistry · doi:10.1071/ch12321 · Cited by 13
Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation
McCormack, P. L. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0269-6 · Cited by 13
Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy
Phipps, C., Linenberger, M. L., Holmberg, L., Green, D., Becker, P. S., Connelly‐Smith, L. S., Klippel, Z. K., Burwick, N. R., Gopal, A. K., Bensinger, W., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.13 · Cited by 13
Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee
Raje, N. S., Faiman, B. M., Harvey, R. D., Kurtin, S. E., Lonial, S., Kumar, S. K., Cohen, A. D., Conde, M. Á., Giralt, S., Recine, M. S., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.04.011 · Cited by 13
Self-citation
Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the M yeloma F oundation of A ustralia M edical and S cientific A dvisory G roup
Quach, H., Joshua, D. E., Ho, J., Szer, J., Spencer, A. G., Harrison, S. J., Mollee, P. N., Roberts, A. W., Horvath, N., Talulikar, D., et al. (2015) · Internal Medicine Journal · doi:10.1111/imj.12640 · Cited by 13
The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma
Mel, S. D., Chen, Y., Gopalakrishnan, S., Ooi, M. G. M., Teo, C., Tan, D., Teo, M., Tso, A. C. Y., Lee, L. Y. K., Nagarajan, C., et al. (2016) · Singapore Medical Journal · doi:10.11622/smedj.2016150 · Cited by 14
Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation
Kawamura, K., Takamatsu, H., Ikeda, T., Komatsu, T., Aotsuka, N., Amano, I., Yamamoto, G., Watanabe, K., Ohno, Y., Matsue, K., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.02.015 · Cited by 12
Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents
Nathwani, N., Larsen, J. T., & Kapoor, P. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0310-9 · Cited by 12
Impact of lenalidomide‐based induction therapy on the mobilization of CD34+ cells, blood graft cellular composition, and post‐transplant recovery in myeloma patients: a prospective multicenter study
Partanen, A., Valtola, J., Silvennoinen, R. H., Ropponen, A., Siitonen, T., Putkonen, M., Sankelo, M., Pelkonen, J., Mäntymaa, P., Varmavuo, V., et al. (2017) · Transfusion · doi:10.1111/trf.14220 · Cited by 13
Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time.
Kazandjian, D. G., & Landgren, O. (2019) · PubMed · Cited by 12
Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies
Devine, S. M., & Horowitz, M. M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01623 · Cited by 12
Self-citation
Post-Transplant Maintenance Treatment Options in Multiple Myeloma
Karam, D., & Kumar, S. K. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00143-7 · Cited by 12
Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma
Marneni, N., & Chakraborty, R. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00631-7 · Cited by 12
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis
Pasvolsky, O., Yeshurun, M., Fraser, R. A., Estrada‐Merly, N., Rozovski, U., Shargian, L., Assal, A., Banerjee, R. K., Bumma, N., Gale, R. P., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01455-y · Cited by 12
Self-citation
The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma
Salafian, K., Mazimba, C., Volodin, L., Varadarajan, I., Pilehvari, A., You, W., Knio, Z. O., & Ballen, K. K. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02200-x · Cited by 12
Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic
Mir, M. A., Kapoor, P., Kumar, S. K., Pandey, S., Dispenzieri, A. A., Lacy, M. Q., Dingli, D., Hogan, W. J., Buadi, F. K., Hayman, S. R., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.03.016 · Cited by 12
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment
Zago, M., Oehrlein, K., Rendl, C., Hahn‐Ast, C., Kanz, L., & Weisel, K. C. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2149-2 · Cited by 12
Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma.
Cruz, M. P. (2016) · PubMed Central · Cited by 12
Standardisation of minimal residual disease in multiple myeloma
Innao, V., Allegra, A., Russo, S., Gerace, D. G., Vaddinelli, D., Alonci, A., Allegra, A. G., & Musolino, C. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12732 · Cited by 12
Two new polymorphs and one dihydrate of lenalidomide: solid-state characterization study
Jia, L., Li, Z., & Gong, J. (2019) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2019.1641517 · Cited by 13
Effect of Cosolvents on the Solubility of Lenalidomide and Thermodynamic Model Correlation of Data
Li, R., Liu, L., Khan, A., Li, C., He, Z., Zhao, J. Y., & Han, D. (2019) · Journal of Chemical & Engineering Data · doi:10.1021/acs.jced.9b00331 · Cited by 12
Moving Toward Continuous Therapy in Multiple Myeloma
Bonello, F., Cetani, G., Bertamini, L., Gay, F., & Larocca, A. (2019) · Clinical Hematology International · doi:10.2991/chi.d.191101.001 · Cited by 13
Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study
Arora, M., Chen, Y., Hageman, L., Wu, J., Landier, W., Francisco, L., Kung, M., Ness, E., Bosworth, A., Pamukçuoğlu, M., et al. (2020) · Cancer · doi:10.1002/cncr.32941 · Cited by 14
Self-citation
Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma
Mithraprabhu, S., Kalff, A., Gartlan, K. H., Savvidou, I., Khong, T. T., Ramachandran, M., Cooke, R. E., Bowen, K. M., Hill, G. R., Reynolds, J., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17080 · Cited by 12
Nonselective proteasome inhibitors in multiple myeloma and future perspectives
Gavriatopoulou, M., Malandrakis, P., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999411 · Cited by 13
Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy
Krishnan, A. Y., Vij, R., Keller, J., Dhakal, B., & Hari, P. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159016 · Cited by 12
Self-citation
U nited K ingdom M yeloma F orum ( UKMF ) position statement on the use of bendamustine in myeloma
Pratt, G., Bowcock, S. J., Lai, M., Bell, S., Bird, J. M., D’Sa, S., Cavenagh, J. D., Cook, G., Morgan, G. J., Owen, R. G., et al. (2013) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12097 · Cited by 12
Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of A ustralia M edical and S cientific A dvisory G roup
Quach, H., Joshua, D., Ho, J., Szer, J., Spencer, A. G., Harrison, S. J., Mollee, P. N., Roberts, A. W., Horvath, N., Talaulikar, D., et al. (2015) · Internal Medicine Journal · doi:10.1111/imj.12688 · Cited by 12
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide
Rollison, D. E. M., Komrokji, R. S., Lee, J., Hampras, S. S., Fulp, W. J., Fisher, K. J., Baz, R., Nishihori, T., Xu, Q., Olesnyckyj, M., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1207763 · Cited by 12
Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
Jung, S., Koh, Y., Kim, M. K., Kim, J. S., Moon, J., Min, C., Yoon, D. H., Yoon, S. S., Lee, J., Hong, C. M., et al. (2025) · Blood Research · doi:10.1007/s44313-025-00055-9 · Cited by 11
Current Approaches to the Initial Treatment of Symptomatic Multiple Myeloma
Jasielec, J. K., & Jakubowiak, A. J. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.3 · Cited by 12
Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
Patel, K. K., Shah, J. J., Feng, L., Lee, H. C., Manasanch, E. M., Olsem, J. B., Morphey, A. N., Huo, X. J., Thomas, S. K., Bashir, Q., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3420 · Cited by 11
Self-citation
Single‐agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience
Pasvolsky, O., Milton, D. R., Masood, A., Sami, S. S., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., Ramdial, J., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27029 · Cited by 11
Self-citation
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine, and Total Body Irradiation Conditioning Is Effective in an Elderly and Infirm Population
Brammer, J. E., Stentz, A., Gajewski, J., Curtin, P. T., Hayes‐Lattin, B., Kovacsovics, T. J., Leis, J. F., Meyers, G., Nemecek, E. R., Subbiah, N., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.09.024 · Cited by 11
Self-citation
Myeloma Propagating Cells, Drug Resistance and Relapse
Karadimitris, A., Chaidos, A., Caputo, V. S., Goudevenou, K., Ponnusamy, K., & Xiao, X. (2015) · Stem Cells · doi:10.1002/stem.2199 · Cited by 11
Pomalidomide Desensitization in a Patient Hypersensitive to Immunomodulating Agents
Seki, J. T., Sakurai, N., Lam, W., & Reece, D. E. (2017) · Current Oncology · doi:10.3747/co.24.3572 · Cited by 11
Short overview on the current standard of treatment in newly diagnosed multiple myeloma
Willenbacher, E., Balog, A., & Willenbacher, W. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0383-3 · Cited by 13
Combined Use of Ninjin'yoeito Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study
Ito, T., Konishi, A., Tsubokura, Y., Azuma, Y., Hotta, M., Yoshimura, H., Nakanishi, T., Fujita, S., Nakaya, A., Satake, A., et al. (2018) · Frontiers in Nutrition · doi:10.3389/fnut.2018.00072 · Cited by 11
Prognosis value of RBBP8 expression in plasma cell myeloma
Zhang, W., Song, Y., He, X., Liu, X., Zhang, Y., Yang, Z., Yang, P., Wang, J., Hu, K., Liu, W., et al. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-018-0069-3 · Cited by 11
Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond
Kocoglu, M. H., & Badros, A. Z. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1756258 · Cited by 11
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma
Noonan, K. A., & Colson, K. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.005 · Cited by 12
The therapeutic effect of modified Huangqi Guizhi Wuwu Tang for multiple myeloma
Tian, M., & Huang, H. (2017) · Medicine · doi:10.1097/md.0000000000009074 · Cited by 11
Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant
Pourmoussa, A., Spielberger, R. T., Cai, J., Khoshbin, O., Farol, L. T., Cao, T. M., & Sahebi, F. (2019) · The Permanente Journal · doi:10.7812/tpp/19.012 · Cited by 11
Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients
Blocka, J., Hielscher, T., Goldschmidt, H., & Hillengaß, J. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.03.006 · Cited by 11
Cutaneous adverse reactions to lenalidomide
Imbesi, S., Allegra, A., Calapai, G., Musolino, C., & Gangemi, S. (2013) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2013.07.005 · Cited by 11
The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT
Hwang, A., Hayden, P. J., Pawlyn, C., McLornan, D. P., & Garderet, L. (2024) · British Journal of Haematology · doi:10.1111/bjh.19353 · Cited by 10
Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Hicks, L. K., Messersmith, H. J., Hadidi, S. S. A. A., Banerjee, R. K., Derman, B. A., Kumar, S. K., Wildes, T. M., Bal, S., Bhella, S., Chmielewski, C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02587 · Cited by 11
Self-citation
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma
Joks, M., Jurczyszyn, A. J., Machaczka, M., Skotnicki, A. B., & Komarnicki, M. A. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12412 · Cited by 11
Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?
Barosi, G., & Gale, R. P. (2019) · Leukemia · doi:10.1038/s41375-019-0383-2 · Cited by 10
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis
Bonello, F., Pulini, S., Ballanti, S., Gentile, M., Spada, S., Annibali, O., Omedè, P., Ronconi, S., Cangialosi, C., Podda, L., et al. (2019) · Cancers · doi:10.3390/cancers11111735 · Cited by 11
Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment
Groot, C. A. U., Ramsden, R., Lee, D., Boersma, J., Zweegman, S., & Dhanasiri, S. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13497 · Cited by 10
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease
Richardson, P. G. G., Mateos, M., Vangsted, A. J., Ramasamy, K., Abildgaard, N., Ho, P. J., Quach, H., & Bahlis, N. J. (2022) · Expert Review of Proteomics · doi:10.1080/14789450.2022.2142564 · Cited by 11
Self-citation
Mature results of MM‐011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma
Lazaryan, A., Hussein, M. A., Reu, F. J., Faiman, B. M., Habecker, B., Karam, M. A., Reed, J., Hamilton, K. M., Waksman, J. A., Bruening, K., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23639 · Cited by 10
Current Treatment Strategies with Lenalidomide in Multiple Myeloma and Future Perspectives
Larocca, A., Cavallo, F., Mina, R., Boccadoro, M., & Palumbo, A. P. (2012) · Future Oncology · doi:10.2217/fon.12.124 · Cited by 10
From evidence to clinical practice in blood and marrow transplantation
Khera, N. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.04.001 · Cited by 10
Role of Consolidation Therapy in Transplant Eligible Multiple Myeloma Patients
Cavo, M., Brioli, A., Tacchetti, P., Zannetti, B. A., Mancuso, K., & Zamagni, E. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.001 · Cited by 10
The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation
Munker, R., Shi, R., Nair, B. S., Devarakonda, S. S., Cotelingam, J. D., McLarty, J. W., Mills, G. M., & Glass, J. (2015) · Acta Haematologica · doi:10.1159/000440970 · Cited by 10
Is it possible to cure myeloma without allogeneic transplantation?
Katodritou, E., Papadaki, S., Konstantinidou, P., & Terpos, E. (2016) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2016.01.015 · Cited by 10
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial
Parrish, C., Morris, C., Williams, C. D., Cairns, D. A., Cavenagh, J. D., Snowden, J. A., Ashcroft, J., Cavet, J., Hunter, H. M., Bird, J. M., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.01.016 · Cited by 10
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma
Mark, T. M., Guarneri, D., Forsberg, P. A., Rossi, A., Pearse, R. N., Perry, A., Pekle, K. A., Tegnestam, L., Greenberg, J., Shore, T. B., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.03.007 · Cited by 10
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Cerrato, C., Raimondo, F. D., Paoli, L. D., Spada, S., Patriarca, F. F., Crippa, C., Mina, R., Guglielmelli, T., Ben‐Yehuda, D., Oddolo, D., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2641-5 · Cited by 10
Chart Review Across EU5 in MM Post-ASCT Patients
Ashcroft, J., Judge, D., Dhanasiri, S., Taylor‐Stokes, G., & Middleton‐Dalby, C. (2018) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2018-0004 · Cited by 10
The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells
Kibata, K., Ito, T., Inaba, M., Tanaka, A., Iwata, R., Inagaki‐Katashiba, N., Phan, V. T. X., Satake, A., & Nomura, S. (2019) · Journal of Blood Medicine · doi:10.2147/jbm.s206459 · Cited by 10
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
Stroh, J., Seckinger, A., Heider, M., Rudelius, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H. J., Bertsch, U., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005532 · Cited by 10
Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma
Bringhen, S., Gay, F., Pautasso, C., Cerrato, C., Boccadoro, M., & Palumbo, A. P. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.712685 · Cited by 10
Pulmonary toxicity associated with the use of lenalidomide: Case report of late-onset acute respiratory distress syndrome and literature review
Mankikian, J., Lioger, B., Diot, É., d'Halluin, P., Lissandre, S., Marchand-Adam, S., Mercier, E., & Beau-Salinas, F. (2013) · Heart & Lung · doi:10.1016/j.hrtlng.2013.11.007 · Cited by 10
Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma—Real life experience of a tertiary cancer center
Joao, C. M., Coelho, I., Costa, C. S., Esteves, S., & Lúcio, P. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2164-3 · Cited by 10
Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision‐making
Clark, C. A., Cornell, R. F., Scott, E. C., Chung, J., & Costa, L. J. (2016) · American Journal of Hematology · doi:10.1002/ajh.24478 · Cited by 10
Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Laubach, J. P., & Kumar, S. K. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_9 · Cited by 10
Diagnostic and therapeutic approaches to multiple myeloma patients: ‘Real-world’ data from representative multicentre treatment surveys in Germany between 2008 and 2011
Moehler, T. M., Merz, M., Kellermann, L., Goldschmidt, H., & Knauf, W. U. (2016) · Oncology Letters · doi:10.3892/ol.2016.5375 · Cited by 10

Authors: McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R. T., Gabriel, D. A., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Anderson, K. C., & Linker, C.
Affiliations: Roswell Park Comprehensive Cancer Center (US)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Duke University (US)
Memorial Sloan Kettering Cancer Center (US)
Dana-Farber Cancer Institute (US)
Abramson Cancer Center (US)
University of Minnesota Medical Center (US)
Washington University in St. Louis (US)
University of Florida (US)
University of Wisconsin–Madison (US)
State University of New York (US)
Mount Sinai Hospital (US)
Oregon Health & Science University (US)
University of North Carolina at Chapel Hill (US)
BMT Group (United States) (US)
University of California, San Francisco (US)
The University of Texas MD Anderson Cancer Center (US)
University of Chicago (US)
University of Chicago Medical Center (US)
Medical College of Wisconsin (US)
ORCID: McCarthy, Philip L.
Owzar, Kouros
Hofmeister, Craig C.
Hassoun, Hani
Richardson, Paul G.
Giralt, Sergio
Stadtmauer, Edward A.
Weisdorf, Daniel J.
Vij, Ravi
Moreb, Jan S.
Callander, Natalie Scott
Gentile, Teresa
Isola, Luis
Maziarz, Richard T.
Landau, Heather
Martin, Thomas
Qazilbash, Muzaffar H.
McClune, Brian
Jiang, Chen
Bennett, Elizabeth
Kelly, Michael
Rosenbaum, Cara
Hari, Parameswaran
Pasquini, Marcelo C.
Horowitz, Mary M.
Devine, Steven M.
Anderson, Kenneth C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-05-10
Volume: 366
Issue: 19
Pages: 1770-1781
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1114083
PMC: PMC3744390
OpenAlex: W2125721471
Semantic Scholar: b20a8f57aae32a45c1804976b107b4ba1609688f
Cited by: 1,147
References: 42
Citations by year: 2026: 28 · 2025: 30 · 2024: 40 · 2023: 40 · 2022: 51 · 2021: 74 · 2020: 81 · 2019: 70 · 2018: 82 · 2017: 104 · 2016: 107 · 2015: 100 · 2014: 113 · 2013: 144 · 2012: 81
FWCI: 93.26
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
Funders: National Heart, Lung, and Blood Institute (U10HL069334, U10HL069301, U10HL069348, U10HL109526, U01HL069294, U10HL069294, U10HL069330, U10HL069315, U10HL069290, U10HL069286, UG1HL069286, UG1HL069315)
National Cancer Institute (U10CA033601, P50CA100707, U10CA031946, U10CA021115, U24CA076518)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords: lenalidomide, multiple myeloma, autologous stem cell transplantation, maintenance therapy, time to progression, overall survival, secondary malignancies, hematologic adverse events, drug toxicity
MeSH terms: Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks